Call for Abstracts and Travel Awards: All authors notified by email  ︎  18 invited speakers confirmed  ︎  Save your seat! Register here until October 7  ︎  Check the programme at a glance  ︎  Interested in joining the team of volunteers? Apply now!   ︎  Become a partner of #CRSy22  ︎ 
︎    ︎    ︎    

Celso Reis


Group Leader @Institute for Research and Innovation in Health (i3s) & Institute of Molecular Pathology and Immunology of the University of Porto

Professor @ICBAS Institute of Biomedical Sciences Abel Salazar

Invited Professor @Institute of Molecular Pathology and Immunology of the University of Porto


Celso A. Reis is the Head of the Glycobiology in Cancer group at i3S - Institute for Research and Innovation in Health, University of Porto, and Ipatimup – Institute of Molecular Pathology and Immunology of the University of Porto.  He serves as a member of the Board of Directors of i3S. He is also a Professor at the ICBAS Institute of Biomedical Sciences Abel Salazar, University of Porto, and an Institute of Molecular Pathology and Immunology of the University of Porto.

He holds a PhD from the University of Porto and was a research fellow for two years at the University of Copenhagen, Denmark.

Currently he leads an international multidisciplinary team working on Glycobiology in human diseases with focus on cancer at i3S.  My lab investigates the molecular mechanisms controlling glycosylation in cancer, during carcinogenesis and tumor progression, and how to exploit these for novel strategies to improve cancer diagnosis, prognosis and cancer patient stratification. We defined the role of glycosyltransferases regulating the biosynthesis of glycans in cancer, including those controlling critical steps on O-glycans, N-glycans, and glycosaminoglycans biosynthesis that impact cancer invasion and metastasis, as well as the tumor microenvironment. In addition, we develop new advanced models and strategies to target cancer-specific glycans and glycoconjugates for cancer therapies.

Celso A. Reis has published 222 peer-reviewed papers as well as several patents, with over 14500 citations and with H-index of 55 (Scopus).

This symposium is supported by QuantOCancer Project funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 810653.